Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04230954
Title Cabozantinib Plus Pembrolizumab for Recurrent, Persistent and/or Metastatic Cervical Cancer
Recruitment Terminated
Gender female
Phase Phase II
Variant Requirements No
Sponsors University of South Alabama
Indications

cervical squamous cell carcinoma

cervical adenocarcinoma

cervical adenosquamous carcinoma

Therapies

Cabozantinib + Pembrolizumab

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.